TScan Therapeutics Raises $140M Via Secondary Stock Offering Of 23M At $2/Share And 47M Pre-funded Warrants At $2/Share
Portfolio Pulse from Benzinga Newsdesk
TScan Therapeutics (NASDAQ:TCRX) has priced a secondary stock offering of 22,989,474 shares at $2.00 per share and 47,010,526 pre-funded warrants at $1.9999 per warrant, expecting to raise approximately $140 million before expenses.

May 26, 2023 | 7:26 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TScan Therapeutics' secondary stock offering and pre-funded warrants could dilute existing shareholders' value, potentially impacting the stock price.
The secondary stock offering and pre-funded warrants will increase the number of outstanding shares, which could dilute the value of existing shares. This may lead to a short-term negative impact on the stock price as investors adjust to the new share structure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100